[1] |
XU ZR, WANG HZ, YANG ZQ, et al. Risk factors analysis of pancreatic ductal stones combined with malignant tumor beside stones[J]. Chin J Dig Surg, 2018, 17(12): 1204-1208. DOI: 10.3760/cma.j.issn.1673-9752.2018.12.011.
徐正荣, 王槐志, 杨智清, 等. 胰管结石合并周围恶性肿瘤的危险因素分析[J]. 中华消化外科杂志, 2018, 17(12): 1204-1208. DOI: 10.3760/cma.j.issn.1673-9752.2018.12.011.
|
[2] |
DREWES AM, BOUWENSE SAW, CAMPBELL CM, et al. Guidelines for the understanding and management of pain in chronic pancreatitis[J]. Pancreatology, 2017, 17(5): 720-731. DOI: 10.1016/j.pan.2017.07.006.
|
[3] |
HU LH, LI ZS. Pancreatic extracorporeal shock wave lithotripsy[J]. J Hepatobiliary Surg, 2016, 24(6): 401-403. DOI: 10.3969/j.issn.1006-4761.2016.06.001.
胡良皞, 李兆申. 胰腺体外震波碎石技术[J]. 肝胆外科杂志, 2016, 24(6): 401-403. DOI: 10.3969/j.issn.1006-4761.2016.06.001.
|
[4] |
Special Committee on Chronic Pancreatitis, Pancreatic Disease Specialized Committee, Chinese Medical Doctor Association. Guideline for the diagnosis and treatment of chronic pancreatitis(2018, Guangzhou)[J]. J Clin Hepatol, 2019, 35(1): 45-51. DOI: 10.3969/j.issn.1001-5256.2019.01.008.
中国医师协会胰腺病专业委员会慢性胰腺炎专委会. 慢性胰腺炎诊治指南(2018, 广州)[J]. 临床肝胆病杂志, 2019, 35(1): 45-51. DOI: 10.3969/j.issn.1001-5256.2019.01.008.
|
[5] |
BASSI C, MARCHEGIANI G, DERVENIS C, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After[J]. Surgery, 2017, 161(3): 584-591. DOI: 10.1016/j.surg.2016.11.014.
|
[6] |
WAN L, ZHAO Q, CHEN J, et al. Expert consensus on the application of pain evaluation questionnaires in China(2020)[J]. Chin J Painol, 2020, 16(3): 177-187. DOI: 10.3760/cma.j.cn101379-20190915-00075.
万丽, 赵晴, 陈军, 等. 疼痛评估量表应用的中国专家共识(2020版)[J]. 中华疼痛学杂志, 2020, 16(3): 177-187. DOI: 10.3760/cma.j.cn101379-20190915-00075.
|
[7] |
CHEN MF, WU JS, TIAN BZ, et al. Classification and surgical management of pancreatic duct stones[J]. Chin J Dig Surg, 2010, 9(5): 348-349. DOI: 10.3760/cma.j.issn.1673-9752.2010.05.010.
陈梅福, 吴金术, 田秉障, 等. 胰管结石的分型和治疗[J]. 中华消化外科杂志, 2010, 9(5): 348-349. DOI: 10.3760/cma.j.issn.1673-9752.2010.05.010.
|
[8] |
WANG LW, LI ZS, LI SD, et al. A multi-center survey on chronic pancreatitis in China[J]. Chin J Pancreatol, 2007, 7(1): 1-5. DOI: 10.3760/cma.j.issn.1674-1935.2007.01.001.
王洛伟, 李兆申, 李淑德, 等. 慢性胰腺炎全国多中心流行病学调查[J]. 胰腺病学, 2007, 7(1): 1-5. DOI: 10.3760/cma.j.issn.1674-1935.2007.01.001.
|
[9] |
YOU YL, GONG JP. Diagnosis and treatment of pancreatic duct stone[J]. Int J Surg, 2021, 48(6): 405-410. DOI: 10.3760/cma.j.cn115396-20210607-00208.
游宇来, 龚建平. 胰管结石的诊疗现状[J]. 国际外科学杂志, 2021, 48(6): 405-410. DOI: 10.3760/cma.j.cn115396-20210607-00208.
|
[10] |
ISSA Y, BRUNO MJ, BAKKER OJ, et al. Treatment options for chronic pancreatitis[J]. Nat Rev Gastroenterol Hepatol, 2014, 11(9): 556-564. DOI: 10.1038/nrgastro.2014.74.
|
[11] |
AN DJ, AN L, ZHANG C, et al. Clinical analysis of 76 cases of chronic pancreatitis complicated with pancreatic duct stones. [J]. Chin J Pancreatol, 2018, 18(4): 267-270. DOI: 10.3760/cma.j.issn.1674-1935.2018.04.014.
安东均, 安琳, 张成, 等. 慢性胰腺炎胰管结石76例临床分析[J]. 中华胰腺病杂志, 2018, 18(4): 267-270. DOI: 10.3760/cma.j.issn.1674-1935.2018.04.014.
|
[12] |
ERCP Group, Chinese Society of Digestive Endoscopology, Biliopancreatic Group, Chinese Association of Gastroenterologist and Hepatologis, National Clinical Research Centerfor Digestive Diseases. Chinese Guidelines for ERCP(2018)[J]. J Clin Hepatol, 2018, 34(12): 2537-2554. DOI: 10.3969/j.issn.1001-5256.2018.12.009.
中华医学会消化内镜学分会ERCP学组, 中国医师协会消化医师分会胆胰学组, 国家消化系统疾病临床医学研究中心. 中国经内镜逆行胰胆管造影术指南(2018版)[J]. 临床肝胆病杂志, 2018, 34(12): 2537-2554. DOI: 10.3969/j.issn.1001-5256.2018.12.009.
|
[13] |
RÖSCH T, DANIEL S, SCHOLZ M, et al. Endoscopic treatment of chronic pancreatitis: a multicenter study of 1000 patients with long-term follow-up[J]. Endoscopy, 2002, 34(10): 765-771. DOI: 10.1055/s-2002-34256.
|
[14] |
YIN ZY, LIU Q, LI XM, et al. Endoscopic retrograde cholangio-pancreatography for pancreatic duct stones[J/CD]. Chin J Hepat Surg(Electronic Edition), 2020, 9(5): 466-470. DOI: 10.3877/cma.j.issn.2095-3232.2020.05.016.
尹振宇, 刘乾, 李晓梅, 等. ERCP治疗胰管结石[J/CD]. 中华肝脏外科手术学电子杂志, 2020, 9(5): 466-470. DOI: 10.3877/cma.j.issn.2095-3232.2020.05.016.
|
[15] |
HE X, YOU J, JIN X, et al. Rational selection of surgical treatment for pancreatic duct stones[J]. J Clin Surg, 2018, 26(7): 29-30. DOI: 10.3969/j.issn.1005-6483.2018.07.017.
何鑫, 游建, 金鑫, 等. 胰管结石外科治疗体会[J]. 临床外科杂志, 2018, 26(7): 29-30. DOI: 10.3969/j.issn.1005-6483.2018.07.017.
|
[16] |
GU F, CHENG R, ZHANG ST. Use of ERCP combined with ESWL in the treatment of pancreatic duct stones[J]. Chin J Bases Clin Gen Surg, 2022, 29(2): 141-145. DOI: 10.7507/1007-9424.202201009.
谷丰, 程芮, 张澍田. ERCP联合ESWL在胰管结石治疗中的应用[J]. 中国普外基础与临床杂志, 2022, 29(2): 141-145. DOI: 10.7507/1007-9424.202201009.
|
[1] | Jun GAO, Huan CHEN, Yan LIU, Feng ZHANG, Yuzheng ZHUGE. Effect of interleukin-22 on hepatic stellate cell activation and its mechanism[J]. Journal of Clinical Hepatology, 2024, 40(11): 2229-2237. doi: 10.12449/JCH241116 |
[2] | Zhiyi WANG, Guangyue YANG, Wei ZHANG, Yaqiong PU, Xin ZHAO, Wenting MA, Xuling LIU, Liu WU, Le TAO, Cheng LIU. Role of podoplanin in hepatic stellate cell activation and liver fibrosis[J]. Journal of Clinical Hepatology, 2024, 40(3): 533-538. doi: 10.12449/JCH240316 |
[3] | Wentao XIE, Kangkang YU, Qi CHENG, Ning LI. Mechanism of microRNA-223-3p inhibiting hepatic stellate cell activation by targeting microtubule-associated protein 1B[J]. Journal of Clinical Hepatology, 2023, 39(12): 2845-2850. doi: 10.3969/j.issn.1001-5256.2023.12.015 |
[4] | Yuxin YAN, Xiaoyang GAO, Chunyan ZHANG, Rong JIN, Hongwei YUAN, Yuehong MA. Role and mechanism of action of the Mongolian medicine Scabiosa atropurea in inhibiting the proliferation of hepatic stellate cells[J]. Journal of Clinical Hepatology, 2023, 39(6): 1351-1357. doi: 10.3969/j.issn.1001-5256.2023.06.015 |
[5] | Jing PENG, Wei YUAN, Sihan YIN, Kewei SUN. Mechanism of NLRP3 inflammasome promoting hepatic stellate cell activation[J]. Journal of Clinical Hepatology, 2022, 38(11): 2611-2615. doi: 10.3969/j.issn.1001-5256.2022.11.035 |
[6] | Ning YANG, Jiang DENG, Yikai WANG, Sha CHANG, Ning GAO, Wenjun WANG, Shuangsuo DANG, Juanjuan SHI. Role and mechanism of caffeic acid phenethyl ester in hepatic stellate cell[J]. Journal of Clinical Hepatology, 2022, 38(10): 2273-2278. doi: 10.3969/j.issn.1001-5256.2022.10.014 |
[7] | Tingyu REN, Hezhongrong NIE, Lijia XIAO, Fangnan LIN, Daming WANG, Chunli SONG, Yiwen ZHOU. Effect of hepatitis B x gene-overexpressed hepatocytes on the proliferation and activation of hepatic stellate cells and related mechanism[J]. Journal of Clinical Hepatology, 2021, 37(7): 1561-1566. doi: 10.3969/j.issn.1001-5256.2021.07.017 |
[8] | Yao YunTing, Zhou YuanZhong, Liu Jun. Role of exosomes in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(10): 2333-2339. doi: 10.3969/j.issn.1001-5256.2020.10.038 |
[9] | Yang MiaoMiao, Wu ZhiHui, Tu ZhengKun. Hepatitis B virus-mediated interaction between hepatic stellate cells and innate immune cells[J]. Journal of Clinical Hepatology, 2020, 36(4): 891-894. doi: 10.3969/j.issn.1001-5256.2020.04.040 |
[10] | Huang XiaoLi, Liu YingYing, Cong Min. Research advances in drug carrier systems targeting hepatic stellate cells[J]. Journal of Clinical Hepatology, 2020, 36(1): 208-212. doi: 10.3969/j.issn.1001-5256.2020.01.050 |
[11] | Li TianYang, Tu ZhengKun, Su LiShan. Regulatory effect of natural killer cells on hepatic stellate cells and their role in liver fibrosis[J]. Journal of Clinical Hepatology, 2017, 33(3): 558-562. doi: 10.3969/j.issn.1001-5256.2017.03.036 |
[12] | Zhao WeiHua, Wang YanHong, Cong Min. Regulatory effect of transforming growth factor-β on activation of hepatic stellate cells[J]. Journal of Clinical Hepatology, 2016, 32(11): 2195-2198. doi: 10.3969/j.issn.1001-5256.2016.11.044 |
[13] | Ren ChangZhen, Hao LiSen. Signal transduction involved in activation of hepatic stellate cells[J]. Journal of Clinical Hepatology, 2015, 31(3): 452-456. doi: 10.3969/j.issn.1001-5256.2015.03.034 |
[14] | Zhang Zhan, Ping Jian, Xu LieMing. Screening Chinese medicine components for inhibition of human hepatic stellate cell migration[J]. Journal of Clinical Hepatology, 2012, 28(3): 183-188+191. |
[15] | Weng ShanGeng, Xu ChangGuo, Sun Ying, Shi Zheng, Lin LiJuan. Study on the apoptosis of rat hepatic stellate cells induced by kapamycin[J]. Journal of Clinical Hepatology, 2012, 28(3): 219-222. |
[16] | Lu XiaoJu, Chen YongPing, Yang Tao, Cheng Yuan, Jin XiaoZhi, Shen ChunYan, Liu Jun, Wang ChunYing, Wang XiaoDong, Lin Zhuo. The influence of regulatory T cells in hepatic stellate cell proliferation and HA secretion[J]. Journal of Clinical Hepatology, 2012, 28(1): 39-43. |
[17] | Zhang LiLi, Guo XiaoHong, Liu LiXin, Zhang QianQian. IGFBPrP1 siRNA induced apoptosis in rat hepatic stellate cells and its mechanism[J]. Journal of Clinical Hepatology, 2011, 27(9): 965-969+979. |
[18] | Dai YongMei, Cai LiMian, Lin Leng. The effect of octreotide on the expression of collagen、TIMP-1 and MMP-2 in HSC1[J]. Journal of Clinical Hepatology, 2008, 24(5): 332-334. |
[19] | Yang WeiFeng, Chen HouChang, Li Lin. Effect of Curcumin on proliferation and extracellular matrix secretion of rat hepatic stellate cells in vitro[J]. Journal of Clinical Hepatology, 2004, 20(3): 142-143. |
[20] | Cheng JiLin, Zhou Xin, Li DingGuo, Wei HongShan, Huang Xin, Wang ZhiRong, Zhan YuTao, Zhang Jing, Xu QinFang, Lu HanMing. RGDS peptides inhibit hepatic stellate cells synthesizing extracellular matrix stimulated by transforming growth factor beta.[J]. Journal of Clinical Hepatology, 2001, 17(3): 173-175. |
1. | 李晶津,王佳玉,金泽宁. 昼夜节律对肝脏胆固醇代谢的影响. 中西医结合肝病杂志. 2022(12): 1110-1113 . ![]() |